Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924560 | 1.00 | HRH3 (0.48) | HRH3NAMPTLMNAPOLBPAX8 | |
| SCHEMBL2923194 | 0.89 | WNT1 (0.44) | HRH3NAMPTLMNAPOLBMAP4K4 | |
| SCHEMBL2923192 | 0.89 | WNT1 (0.44) | HRH3NAMPTLMNAPOLBMAP4K4 | |
| SCHEMBL2930662 | 0.86 | HRH3 (0.46) | HRH3NAMPTLMNAPOLBMAPT | |
| SCHEMBL2930661 | 0.86 | HRH3 (0.46) | HRH3NAMPTLMNAPOLBMAPT | |
| SCHEMBL2924552 | 0.84 | HRH3 (0.47) | HRH3LMNAPOLBMAPT | |
| SCHEMBL2924554 | 0.84 | HRH3 (0.47) | HRH3LMNAPOLBMAPT | |
| SCHEMBL2929879 | 0.84 | HRH3 (0.48) | HRH3LMNAPOLBMAPTKMT2A | |
| SCHEMBL2929881 | 0.84 | HRH3 (0.48) | HRH3LMNAPOLBMAPTKMT2A | |
| SCHEMBL2930104 | 0.83 | HRH3 (0.57) | HRH3NAMPTLMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | claimed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | claimed |
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | HRH3, HRH4, HCAR2 | HRH3 1/4885NAMPT 2220/4885LMNA 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.